NO20083910L - Forbedret prodroge av CC-1065 analoger - Google Patents

Forbedret prodroge av CC-1065 analoger

Info

Publication number: NO20083910L
Authority: NO; Norway
Prior art keywords: prodrug; analogues; protecting group; prodrugs; cytotoxic
Prior art date: 2006-03-07

Application number

NO20083910A

Other languages

English (en)

Norwegian (no)

Inventor

Robert Zhao

Ravi V J Chan

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-03-07

Filing date

2008-09-12

Publication date

2008-12-01

2008-09-12 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2008-12-01 Publication of NO20083910L publication Critical patent/NO20083910L/no

Links

229940002612 prodrug Drugs 0.000 title abstract 5
239000000651 prodrug Substances 0.000 title abstract 5
231100000433 cytotoxic Toxicity 0.000 abstract 2
230000001472 cytotoxic effect Effects 0.000 abstract 2
125000006239 protecting group Chemical group 0.000 abstract 2
230000001225 therapeutic effect Effects 0.000 abstract 2
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 abstract 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 abstract 1
UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 abstract 1
UOWVMDUEMSNCAV-UHFFFAOYSA-N antibiotic cc 1065 Chemical compound N1C=2C(OC)=C(O)C=3N(C(N)=O)CCC=3C=2C=C1C(=O)N1CCC(C=2C=3)=C1C(O)=C(OC)C=2NC=3C(=O)N1CC2CC22C1=CC(=O)C1=C2C(C)=CN1 UOWVMDUEMSNCAV-UHFFFAOYSA-N 0.000 abstract 1
239000003972 antineoplastic antibiotic Substances 0.000 abstract 1
238000006243 chemical reaction Methods 0.000 abstract 1
239000003153 chemical reaction reagent Substances 0.000 abstract 1
239000002254 cytotoxic agent Substances 0.000 abstract 1
229940127089 cytotoxic agent Drugs 0.000 abstract 1
231100000599 cytotoxic agent Toxicity 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
230000002255 enzymatic effect Effects 0.000 abstract 1
BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Virology (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Indole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NO20083910A 2006-03-07 2008-09-12 Forbedret prodroge av CC-1065 analoger NO20083910L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP06290379A EP1832577A1 (en)	2006-03-07	2006-03-07	Improved prodrugs of CC-1065 analogs
PCT/IB2007/000521 WO2007102069A1 (en)	2006-03-07	2007-03-06	Improved prodrugs of cc-1065 analogs

Publications (1)

Publication Number	Publication Date
NO20083910L true NO20083910L (no)	2008-12-01

Family

ID=36679356

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20083910A NO20083910L (no)	2006-03-07	2008-09-12	Forbedret prodroge av CC-1065 analoger

Country Status (18)

Country	Link
US (2)	US8012978B2 (pt)
EP (2)	EP1832577A1 (pt)
JP (1)	JP2009529030A (pt)
KR (1)	KR20080106919A (pt)
AR (1)	AR059767A1 (pt)
AU (1)	AU2007222123A1 (pt)
BR (1)	BRPI0708654A2 (pt)
CA (1)	CA2642870A1 (pt)
DO (1)	DOP2007000041A (pt)
EA (1)	EA200870327A1 (pt)
IL (1)	IL193673A0 (pt)
MA (1)	MA30322B1 (pt)
MX (1)	MX2008011431A (pt)
NO (1)	NO20083910L (pt)
PE (1)	PE20080691A1 (pt)
TW (1)	TW200813028A (pt)
UY (1)	UY30190A1 (pt)
WO (1)	WO2007102069A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7589180B2 (en)	2001-05-11	2009-09-15	Abbott Laboratories Inc.	Specific binding proteins and uses thereof
US20100056762A1 (en)	2001-05-11	2010-03-04	Old Lloyd J	Specific binding proteins and uses thereof
US6756397B2 (en) *	2002-04-05	2004-06-29	Immunogen, Inc.	Prodrugs of CC-1065 analogs
EA020324B1 (ru)	2006-07-18	2014-10-30	Санофи-Авентис	АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ
EP2126127B1 (en) *	2007-01-25	2016-09-28	Dana-Farber Cancer Institute, Inc.	Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
CA2680854C (en) *	2007-03-15	2017-02-14	Ludwig Institute For Cancer Research	Treatment method using egfr antibodies and src inhibitors and related formulations
US9901567B2 (en)	2007-08-01	2018-02-27	Syntarga B.V.	Substituted CC-1065 analogs and their conjugates
US9283276B2 (en)	2007-08-14	2016-03-15	Ludwig Institute For Cancer Research Ltd.	Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof
US20090155289A1 (en) *	2007-11-01	2009-06-18	Steve Roberts	Furin-cleavable peptide linkers for drug-ligand conjugates
MX2011004625A (es)	2008-11-03	2011-07-20	Syntarga Bv	Analogos cc-1065 novedosos y sus conjugados.
FR2947269B1 (fr)	2009-06-29	2013-01-18	Sanofi Aventis	Nouveaux composes anticancereux
FR2949469A1 (fr)	2009-08-25	2011-03-04	Sanofi Aventis	Derives anticancereux, leur preparation et leur application en therapeutique
US20110076232A1 (en) *	2009-09-29	2011-03-31	Ludwig Institute For Cancer Research	Specific binding proteins and uses thereof
UY32913A (es)	2009-10-02	2011-04-29	Sanofi Aventis	Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero
UY32914A (es)	2009-10-02	2011-04-29	Sanofi Aventis	Anticuerpos que se usan específicamente al receptor epha2
CA2956934C (en)	2010-04-21	2019-07-09	Syntarga B.V.	Novel conjugates of cc-1065 analogs and bifunctional linkers
FR2963007B1 (fr)	2010-07-26	2013-04-05	Sanofi Aventis	Derives anticancereux, leur preparation et leur application therapeutique
CA2868447C (en)	2012-03-30	2020-09-15	The Scripps Research Institute	Cyclic prodrugs of duocarmycin analogs
EP3210627B1 (en)	2012-07-12	2022-12-21	Hangzhou Dac Biotech Co., Ltd	Conjugates of cell binding molecules with cytotoxic agents
AU2012395148B2 (en)	2012-11-24	2016-10-27	Hangzhou Dac Biotech Co., Ltd.	Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
WO2014089177A2 (en)	2012-12-04	2014-06-12	Massachusetts Institute Of Technology	Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
MX368396B (es)	2014-01-10	2019-10-01	Synthon Biopharmaceuticals Bv	Conjugados de anticuerpo-farmaco (adc) de duocarmicina que muestran actividad antitumoral in vivo mejorada.
HRP20160797T1 (hr)	2014-01-10	2016-08-12	Synthon Biopharmaceuticals B.V.	Duokarmicin adsc, namijenjen upotrebi u liječenju raka endometrija
AU2015205574B2 (en)	2014-01-10	2019-08-15	Byondis B.V.	Method for purifying Cys-linked antibody-drug conjugates
FI3122757T3 (fi)	2014-02-28	2023-10-10	Hangzhou Dac Biotech Co Ltd	Varautuneita linkkereitä ja niiden konjugointikäyttötapoja
EP3319936B1 (en)	2015-07-12	2025-12-17	Hangzhou Dac Biotech Co., Ltd.	Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en)	2015-07-15	2017-12-12	Suzhou M-Conj Biotech Co., Ltd.	Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
TW201808336A (zh)	2016-05-11	2018-03-16	賽諾菲公司	用抗ｍｕｃ１類美登素免疫綴合物抗體治療腫瘤的治療方案
US10918627B2 (en)	2016-05-11	2021-02-16	Massachusetts Institute Of Technology	Convergent and enantioselective total synthesis of Communesin analogs
AU2016429272A1 (en)	2016-11-14	2019-05-02	Hangzhou Dac Biotech Co., Ltd.	Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
US11932650B2 (en)	2017-05-11	2024-03-19	Massachusetts Institute Of Technology	Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en)	2017-10-13	2020-05-05	Massachusetts Institute Of Technology	Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en)	2019-06-05	2022-12-27	Massachusetts Institute Of Technology	Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
EP4126833B1 (en) *	2020-03-23	2026-05-20	Helmholtz Zentrum Infektionsforschung Gmbh	N-PHENYL-3-MERCAPTOPROPANAMIDES DERIVATIVES AS METALLO-BETA-LACTAMASES INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS
US12030888B2 (en)	2021-02-24	2024-07-09	Massachusetts Institute Of Technology	Himastatin derivatives, and processes of preparation thereof, and uses thereof
CN117980327A (zh)	2021-11-03	2024-05-03	杭州多禧生物科技有限公司	抗体的特异性偶联

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5208020A (en) *	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5278324A (en) *	1990-08-28	1994-01-11	Virginia Tech Intellectual Properties, Inc.	Water soluble derivatives of taxol
CA2076465C (en) *	1992-03-25	2002-11-26	Ravi V. J. Chari	Cell binding agent conjugates of analogues and derivatives of cc-1065
US5646298A (en) *	1995-06-07	1997-07-08	Procoron, Inc.	Cyclopropylindole prodrugs
US6756397B2 (en) *	2002-04-05	2004-06-29	Immunogen, Inc.	Prodrugs of CC-1065 analogs
US6534660B1 (en) *	2002-04-05	2003-03-18	Immunogen, Inc.	CC-1065 analog synthesis

2006
- 2006-03-07 EP EP06290379A patent/EP1832577A1/en not_active Withdrawn
2007
- 2007-03-05 PE PE2007000236A patent/PE20080691A1/es not_active Application Discontinuation
- 2007-03-06 JP JP2008557845A patent/JP2009529030A/ja not_active Withdrawn
- 2007-03-06 AR ARP070100932A patent/AR059767A1/es unknown
- 2007-03-06 TW TW096107668A patent/TW200813028A/zh unknown
- 2007-03-06 MX MX2008011431A patent/MX2008011431A/es not_active Application Discontinuation
- 2007-03-06 DO DO2007000041A patent/DOP2007000041A/es unknown
- 2007-03-06 AU AU2007222123A patent/AU2007222123A1/en not_active Abandoned
- 2007-03-06 UY UY30190A patent/UY30190A1/es not_active Application Discontinuation
- 2007-03-06 EA EA200870327A patent/EA200870327A1/ru unknown
- 2007-03-06 EP EP07713102A patent/EP1993999A1/en not_active Withdrawn
- 2007-03-06 CA CA002642870A patent/CA2642870A1/en not_active Abandoned
- 2007-03-06 KR KR1020087021749A patent/KR20080106919A/ko not_active Withdrawn
- 2007-03-06 WO PCT/IB2007/000521 patent/WO2007102069A1/en not_active Ceased
- 2007-03-06 BR BRPI0708654-7A patent/BRPI0708654A2/pt not_active Application Discontinuation
2008
- 2008-08-25 IL IL193673A patent/IL193673A0/en unknown
- 2008-09-04 US US12/204,082 patent/US8012978B2/en not_active Expired - Fee Related
- 2008-09-12 NO NO20083910A patent/NO20083910L/no not_active Application Discontinuation
- 2008-09-29 MA MA31261A patent/MA30322B1/fr unknown
2011
- 2011-07-15 US US13/184,255 patent/US20110280890A1/en not_active Abandoned

Also Published As

Publication number	Publication date
UY30190A1 (es)	2008-10-31
KR20080106919A (ko)	2008-12-09
AR059767A1 (es)	2008-04-30
BRPI0708654A2 (pt)	2011-06-07
TW200813028A (en)	2008-03-16
PE20080691A1 (es)	2008-06-04
US20090028821A1 (en)	2009-01-29
DOP2007000041A (es)	2007-10-31
EP1832577A1 (en)	2007-09-12
WO2007102069A1 (en)	2007-09-13
IL193673A0 (en)	2009-05-04
JP2009529030A (ja)	2009-08-13
CA2642870A1 (en)	2007-09-13
AU2007222123A1 (en)	2007-09-13
EA200870327A1 (ru)	2009-02-27
US20110280890A1 (en)	2011-11-17
MX2008011431A (es)	2008-09-22
EP1993999A1 (en)	2008-11-26
US8012978B2 (en)	2011-09-06
MA30322B1 (fr)	2009-04-01

Legal Events

Date	Code	Title	Description
2009-10-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
MX2008011431A (es)	2008-09-22	Profarmacos mejorados de analogos de cc-1065.
ECSP109987A (es)	2010-03-31	Métodos y compuestos útiles para preparar inhibidores del co-transportador 2 sodio glucosa
TNSN08463A1 (en)	2010-04-14	Leptomycin derivatives
MX2009011165A (es)	2009-12-09	Formulaciones farmaceuticas que contienen derivados del acido lipoico.
EA200971081A1 (ru)	2010-10-29	Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
EA200870217A1 (ru)	2009-02-27	4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
UY30789A1 (es)	2008-07-31	Derivados de adenina, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
DK1492526T3 (da)	2010-10-11	Konjugerede prodrugs af CC-1065-analoger
UA97834C2 (ru)	2012-03-26	Производные сульфониламида для лечения анормального роста клеток
UY30498A1 (es)	2008-02-29	Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
BR112015018508A2 (pt)	2017-07-18	moduladores de enzimas modificadoras de metila, suas composições e uso
MY151986A (en)	2014-07-31	Adamantyl diamide derivatives and uses of same
MX2011003738A (es)	2011-09-30	Conjugados hpma-docetaxel o gemcitabine y sus usos asociados.
AR082995A1 (es)	2013-01-23	Profarmacos que comprenden un conjugado de conector de exendina
ES2421723T3 (es)	2013-09-05	Análogos de TOFA útiles en el tratamiento de trastornos o afecciones dermatológicas
MX2009011316A (es)	2010-03-26	Derivados del acido lipoico.
UY30572A1 (es)	2008-05-02	N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
PA8855001A1 (es)	2010-07-27	Monocarbamas
GT200600117A (es)	2007-01-19	Nuevos compuestos farmaceuticos
EA201290229A1 (ru)	2012-08-30	Производные спиролактама и их применение
EA201170821A1 (ru)	2011-12-30	Энзастаурин для лечения рака
AR057148A1 (es)	2007-11-21	Combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
ECSP077272A (es)	2007-03-29	Hexadecasacáridos biotinilados, su preparación y su utilización
EA201270277A1 (ru)	2012-09-28	N-ацилированные октасахариды, активирующие рецепторы fgf, их получение и применение в терапии
AR062475A1 (es)	2008-11-12	Combinaciones farmacologicas para el tratameinto de enfermedades de las vias aereas